|
Impact of Antioxidant Excipients on N-nitrosamine Formation and Bioequivalence in Metformin Formulations - Pub
|
|
3
|
475
|
February 11, 2025
|
|
Low nitrite excipients
|
|
11
|
2377
|
November 27, 2024
|
|
Nitrosamnes in PMs & Excipients Questions
|
|
5
|
997
|
November 22, 2024
|
|
Managing Nitrite Impurities: A Supplier-Manufacturer Approach to Mitigate Nitrosamine Risk
|
|
2
|
530
|
October 18, 2024
|
|
Primeros pasos para evaluar nitrosaminas en medicamentos
|
|
5
|
203
|
September 23, 2024
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
0
|
213
|
September 10, 2024
|
|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1636
|
September 5, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
319
|
August 29, 2024
|
|
IPEC Webinar on the role of excipients in determine N-nitrosamine risks
|
|
3
|
455
|
July 24, 2024
|
|
Parts per billion of nitrite in microcrystalline cellulose -Pub
|
|
3
|
1069
|
July 3, 2024
|
|
Risk analysis of nitrosamine impurities in liquid products (essences and flavors)
|
|
3
|
732
|
June 28, 2024
|
|
MEGLUMINE (Methylglucamine)
|
|
18
|
2618
|
June 19, 2024
|
|
Insights from the Lhasa Limited and IPEC Europe Nitrites collaborative meeting
|
|
1
|
513
|
June 16, 2024
|
|
Lactose, Nitrosamine Risk?
|
|
35
|
3317
|
April 6, 2022
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
809
|
June 4, 2024
|
|
N-nitroso cyclamate
|
|
9
|
700
|
March 15, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
507
|
March 13, 2024
|
|
Updated: IPEC Position Paper on Role of Excipients in Determining N-Nitrosamine Risks for Drug Products
|
|
3
|
1130
|
March 7, 2024
|
|
MCC with nitrite levels of 0.1 ppm or less
|
|
4
|
1227
|
March 4, 2024
|
|
A quick (dumb) question
|
|
10
|
1151
|
January 22, 2024
|
|
Low nitrile crosscarmellose sodium
|
|
0
|
429
|
November 6, 2023
|
|
Personal perspective on N-Nitrosamines and recent revision of guidelines
|
|
7
|
798
|
October 27, 2023
|
|
Variation requirements
|
|
2
|
448
|
October 2, 2023
|
|
Apixaban Drug Substance-Related Impurities (NDSRIs)
|
|
3
|
1457
|
September 15, 2023
|
|
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments
|
|
4
|
1241
|
September 7, 2023
|
|
FDA Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities
|
|
11
|
3626
|
July 27, 2023
|
|
Risk Analysis of Colorants and Flavorings in Pharmaceutical Formulations
|
|
9
|
757
|
July 21, 2023
|
|
IPEC Nitrosamine Questionnaire Q&A Excipients
|
|
6
|
1164
|
June 8, 2023
|
|
A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products
|
|
1
|
918
|
June 5, 2023
|
|
Prediction of Nitrosamine formation from Excipients
|
|
19
|
1549
|
February 8, 2023
|